Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $31.51, demonstrating a -1.96% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.57%. Elsewhere, the Dow saw a downswing of 1.61%, while the tech-heavy Nasdaq depreciated by 0.26%.

Coming into today, shares of the company had gained 8.73% in the past month. In that same time, the Medical sector gained 0.06%, while the S&P 500 lost 0.15%.

Analysts and investors alike will be keeping a close eye on the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be -$1.01, reflecting a 146.34% decrease from the same quarter last year.

For the full year, the Zacks Consensus Estimates are projecting earnings of -$4.09 per share and revenue of $0 million, which would represent changes of -28.21% and 0%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for Viking Therapeutics, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 5.44% downward. Viking Therapeutics, Inc. is holding a Zacks Rank of #3 (Hold) right now.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 133, putting it in the bottom 46% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

Quantum Computing Stocks Set To Soar

Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.

Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.

Access the Report Free Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Viking Therapeutics, Inc. (VKTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research